Literature DB >> 22787577

Inhibition of carbonic anhydrase IX as a novel anticancer mechanism.

Claudiu T Supuran1.   

Abstract

Carbonic anhydrases (CA, EC 4.2.1.1) catalyze the interconversion bewteen carbon dioxide and bicarbonate with generation of protons. The carbonic anhydrase isozyme IX (CA IX) is highly overexpresed in hypoxic tumors and shows very restricted expression in normal tissues. CA IX is a dimeric protein possessing very high catalytic activity for the hydration of carbon dioxide to protons and bicarbonate. Its quaternary structure is unique among members of this family of enzymes, allowing for structure-based drug design campaigns of selective inhibitors. Inhibition of CA IX with sulfonamide and/or coumarin inhibitors was recently shown to lead to a potent retardation for the growth of both primary tumors and metastases. Some fluorescent sulfonamides were shown to accumulate only in hypoxic tumor cells overexpressing CA IX, and might be used as diagnostic tools for imaging of hypoxic cancers. Sulfonamide inhibitors were also more effective in inhibiting the growth of the primary tumors when associated with irrdiation. CA IX is thus both a diagnostic and therapeutic validated target for the management of hypoxic tumors normally non-responsive to classical chemio- and radiotherapy.

Entities:  

Keywords:  Carbonic anhydrase; Coumarins; Hypoxia; Sulfonamides; Tumor acidification; Tumor imaging; Tumorigenesis

Year:  2012        PMID: 22787577      PMCID: PMC3394083          DOI: 10.5306/wjco.v3.i7.98

Source DB:  PubMed          Journal:  World J Clin Oncol        ISSN: 2218-4333


  36 in total

1.  Carbonic anhydrases as drug targets.

Authors:  Claudiu T Supuran
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 2.  Carbonic anhydrases: novel therapeutic applications for inhibitors and activators.

Authors:  Claudiu T Supuran
Journal:  Nat Rev Drug Discov       Date:  2008-02       Impact factor: 84.694

3.  Hypoxia-inducible expression of tumor-associated carbonic anhydrases.

Authors:  C C Wykoff; N J Beasley; P H Watson; K J Turner; J Pastorek; A Sibtain; G D Wilson; H Turley; K L Talks; P H Maxwell; C W Pugh; P J Ratcliffe; A L Harris
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

4.  A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing".

Authors:  Brendan L Wilkinson; Laurent F Bornaghi; Todd A Houston; Alessio Innocenti; Claudiu T Supuran; Sally-Ann Poulsen
Journal:  J Med Chem       Date:  2006-11-02       Impact factor: 7.446

Review 5.  Carbonic anhydrases: current state of the art, therapeutic applications and future prospects.

Authors:  Silvia Pastorekova; Seppo Parkkila; Jaromir Pastorek; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2004-06       Impact factor: 5.051

6.  Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.

Authors:  Alessandro Cecchi; Alzbeta Hulikova; Jaromír Pastorek; Silvia Pastoreková; Andrea Scozzafava; Jean-Yves Winum; Jean-Louis Montero; Claudiu T Supuran
Journal:  J Med Chem       Date:  2005-07-28       Impact factor: 7.446

7.  Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model.

Authors:  Ludwig Dubois; Natasja G Lieuwes; Alfonso Maresca; Anne Thiry; Claudiu T Supuran; Andrea Scozzafava; Bradly G Wouters; Philippe Lambin
Journal:  Radiother Oncol       Date:  2009-07-16       Impact factor: 6.280

8.  In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives.

Authors:  Julia K J Ahlskog; Christoph E Dumelin; Sabrina Trüssel; Jessica Mårlind; Dario Neri
Journal:  Bioorg Med Chem Lett       Date:  2009-06-13       Impact factor: 2.823

9.  Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX.

Authors:  Vincenzo Alterio; Mika Hilvo; Anna Di Fiore; Claudiu T Supuran; Peiwen Pan; Seppo Parkkila; Andrea Scaloni; Jaromir Pastorek; Silvia Pastorekova; Carlo Pedone; Andrea Scozzafava; Simona Maria Monti; Giuseppina De Simone
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-14       Impact factor: 11.205

10.  Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors.

Authors:  Ludwig Dubois; Kim Douma; Claudiu T Supuran; Roland K Chiu; Marc A M J van Zandvoort; Silvia Pastoreková; Andrea Scozzafava; Bradly G Wouters; Philippe Lambin
Journal:  Radiother Oncol       Date:  2007-05-14       Impact factor: 6.280

View more
  25 in total

1.  Synthesis of saccharin-glycoconjugates targeting carbonic anhydrase using a one-pot cyclization/deprotection strategy.

Authors:  Akilah B Murray; Marta Quadri; Haoxi Li; Robert McKenna; Nicole A Horenstein
Journal:  Carbohydr Res       Date:  2019-03-19       Impact factor: 2.104

2.  New Dihydrothiazole Benzensulfonamides: Looking for Selectivity toward Carbonic Anhydrase Isoforms I, II, IX, and XII.

Authors:  Rita Meleddu; Simona Distinto; Filippo Cottiglia; Rossella Angius; Pierluigi Caboni; Andrea Angeli; Claudia Melis; Serenella Deplano; Stefano Alcaro; Francesco Ortuso; Claudiu T Supuran; Elias Maccioni
Journal:  ACS Med Chem Lett       Date:  2020-02-13       Impact factor: 4.345

3.  Targeting Tumor Associated Carbonic Anhydrases IX and XII: Highly Isozyme Selective Coumarin and Psoralen Inhibitors.

Authors:  Claudia Melis; Simona Distinto; Giulia Bianco; Rita Meleddu; Filippo Cottiglia; Benedetta Fois; Domenico Taverna; Rossella Angius; Stefano Alcaro; Francesco Ortuso; Marco Gaspari; Andrea Angeli; Sonia Del Prete; Clemente Capasso; Claudiu T Supuran; Elias Maccioni
Journal:  ACS Med Chem Lett       Date:  2018-06-06       Impact factor: 4.345

4.  Monodispersed calcium carbonate nanoparticles modulate local pH and inhibit tumor growth in vivo.

Authors:  Avik Som; Ramesh Raliya; Limei Tian; Walter Akers; Joseph E Ippolito; Srikanth Singamaneni; Pratim Biswas; Samuel Achilefu
Journal:  Nanoscale       Date:  2016-01-08       Impact factor: 7.790

5.  Evaluation of Nonpeptidic Ligand Conjugates for SPECT Imaging of Hypoxic and Carbonic Anhydrase IX-Expressing Cancers.

Authors:  Peng-Cheng Lv; Karson S Putt; Philip S Low
Journal:  Bioconjug Chem       Date:  2016-07-07       Impact factor: 4.774

6.  Tuning the Dual Inhibition of Carbonic Anhydrase and Cyclooxygenase by Dihydrothiazole Benzensulfonamides.

Authors:  Rita Meleddu; Simona Distinto; Filippo Cottiglia; Rossella Angius; Marco Gaspari; Domenico Taverna; Claudia Melis; Andrea Angeli; Giulia Bianco; Serenella Deplano; Benedetta Fois; Sonia Del Prete; Clemente Capasso; Stefano Alcaro; Francesco Ortuso; Matilde Yanez; Claudiu T Supuran; Elias Maccioni
Journal:  ACS Med Chem Lett       Date:  2018-09-17       Impact factor: 4.345

7.  Heterocoumarins Are Selective Carbonic Anhydrase IX and XII Inhibitors with Cytotoxic Effects against Cancer Cells Lines.

Authors:  Andrea Angeli; Elena Trallori; Fabrizio Carta; Lorenzo Di Cesare Mannelli; Carla Ghelardini; Claudiu T Supuran
Journal:  ACS Med Chem Lett       Date:  2018-08-29       Impact factor: 4.345

8.  Utilizing hydrogen sulfide as a novel anti-cancer agent by targeting cancer glycolysis and pH imbalance.

Authors:  Z-W Lee; X-Y Teo; E Y-W Tay; C-H Tan; T Hagen; P K Moore; L-W Deng
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

9.  Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma.

Authors:  Samuele Cazzamalli; Alberto Dal Corso; Dario Neri
Journal:  J Control Release       Date:  2016-11-24       Impact factor: 9.776

10.  Binding of the phage display derived peptide CaIX-P1 on human colorectal carcinoma cells correlates with the expression of carbonic anhydrase IX.

Authors:  Vasileios Askoxylakis; Volker Ehemann; Shoaib Rana; Susanne Krämer; Nuh N Rahbari; Jürgen Debus; Uwe Haberkorn
Journal:  Int J Mol Sci       Date:  2012-10-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.